rs1800624 — AGER -374T/A

AGER −374T/A — The Promoter Variant That Turns Up RAGE Expression

AGER encodes RAGE (Receptor for Advanced Glycation End-Products), a pattern recognition receptor¹¹ pattern recognition receptor
A cell-surface protein in the immunoglobulin superfamily that detects advanced glycation end-products, HMGB1, S100 proteins, and amyloid-beta — triggering NF-κB-mediated inflammatory gene expression found on endothelial cells, neurons, smooth muscle, immune cells, and alveolar epithelium. Unlike the Gly82Ser missense variant (rs2070600), which alters receptor structure, the −374T/A polymorphism acts upstream — it sits in the AGER promoter and directly controls how much RAGE protein is made.

The variant is catalogued on the GRCh38 plus strand with reference allele A and alternate allele T at chr6:32184610. Because AGER is transcribed from the minus strand, published papers use coding-strand notation: the common coding-strand T allele corresponds to plus-strand A, while the functional coding-strand A allele (the one studied as the promoter-active variant) corresponds to plus-strand T. The T allele on the plus strand is the allele that increases RAGE expression.

The Mechanism

In 2001, Hudson et al.²² Hudson et al.
Hudson BI et al. Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes, 2001 used chloramphenicol acetyltransferase (CAT) reporter assays to demonstrate that the −374A coding allele (plus-strand T) increases RAGE promoter-driven transcription approximately threefold compared to the −374T coding allele (P<0.001). The mechanism involves differential binding of nuclear protein extracts from both monocyte- and hepatocyte-derived cell lines, indicating that a transcription factor or co-activator binds preferentially to the A-containing promoter sequence.

Increased RAGE transcription elevates both forms of RAGE: full-length membrane-bound RAGE and soluble RAGE (sRAGE)³³ soluble RAGE (sRAGE)
The secreted truncated form of RAGE that acts as a decoy receptor — capturing circulating AGEs and HMGB1 before they reach cell-surface RAGE, thereby damping inflammatory activation. This dual elevation creates a complex phenotype: more sRAGE circulates as a protective decoy, but more membrane-bound RAGE also sits on cell surfaces ready to fire when AGEs break through the sRAGE buffer. Under low AGE conditions, the sRAGE increase may dominate (hence the protective cardiovascular associations in non-diabetic cohorts). Under chronic hyperglycemia, where AGE loads are overwhelming, the elevated membrane RAGE amplifies inflammation more than the extra sRAGE can neutralize.

The Evidence

Transcriptional activity. The fundamental functional finding — that the −374A coding allele tripled RAGE promoter activity — was established by Hudson et al. (2001)⁴⁴ Hudson et al. (2001) and provides the mechanistic rationale for all subsequent clinical associations. This is a bona fide functional variant, not a tagging SNP.

Diabetic microvascular complications. The most replicated clinical associations involve diabetic nephropathy and retinopathy. Lindholm et al. (2006)⁵⁵ Lindholm et al. (2006)
Lindholm E et al. The −374 T/A polymorphism in the gene encoding RAGE is associated with diabetic nephropathy and retinopathy in type 1 diabetic patients. Diabetologia, 2006 studied 867 type 1 and 2,467 type 2 diabetic patients in Scandinavian cohorts and found that carrying the A/T or A/A coding genotypes (i.e., at least one T on the plus strand) associated with diabetic nephropathy (p=0.006) and sight-threatening retinopathy (p=0.03) in type 1 diabetes. A meta-analysis by Tao et al. (2017)⁶⁶ Tao et al. (2017)
Tao D et al. Association between the RAGE −374T/A gene polymorphism and diabetic retinopathy in T2DM. Rev Assoc Med Bras, 2017 combining 9 case-control studies (1,705 DR cases, 2,236 controls) found that the −374A coding allele (T on the plus strand) conferred OR=1.22 (95% CI 1.05–1.41) in the dominant model and OR=1.26 (95% CI 1.07–1.47) in the heterozygote model for diabetic retinopathy, with risk present in both Asian and Caucasian subgroups. Abdel-Azeez et al. (2009)⁷⁷ Abdel-Azeez et al. (2009)
Abdel-Azeez HA et al. Association of the RAGE −374 T/A gene polymorphism and circulating soluble RAGE with nephropathy in type 1 diabetic patients. Egypt J Immunol, 2009 found OR=2.36 (95% CI 1.1–5.6) for the −374A coding allele (T plus strand) predicting diabetic nephropathy (n=70), with sRAGE levels paradoxically elevated in nephropathy patients — a marker of inflammatory burden rather than protection at that stage of disease.

Cardiovascular disease. In non-diabetic contexts, findings diverge. Falcone et al. (2004)⁸⁸ Falcone et al. (2004)
Falcone C et al. Relationship between the −374T/A RAGE gene polymorphism and angiographic coronary artery disease. Int J Mol Med, 2004 showed in 259 non-diabetic Italians that the −374AA coding genotype (plus-strand TT) was independently protective against angiographically confirmed CAD (OR=0.33, 95% CI 0.15–0.73, p=0.006) — found in 22.6% of controls but only 9.7% of CAD patients. This likely reflects the sRAGE-elevating effect of higher RAGE transcription in a non-AGE-overloaded context. Conversely, Aslan et al. (2024)⁹⁹ Aslan et al. (2024)
Aslan EI et al. Receptor for advanced glycation end products polymorphisms in coronary artery ectasia. Gene, 2024 found that the −374A coding allele (T plus strand) was independently associated with coronary artery ectasia¹⁰¹⁰ coronary artery ectasia
Abnormal dilation of coronary arteries — a distinct clinical entity from obstructive CAD, associated with impaired endothelial function and platelet activation (p<0.001, AUC=0.713 for discrimination), suggesting that in certain vascular phenotypes the elevated RAGE expression drives pathological remodeling.

Type 1 diabetes with poor metabolic control. Pettersson-Fernholm et al. (2003)¹¹¹¹ Pettersson-Fernholm et al. (2003)
Pettersson-Fernholm K et al. The functional −374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients. Diabetes, 2003 found in 996 Finnish T1D patients with HbA1c >9.5% that the −374AA coding genotype (TT on plus strand) was paradoxically protective: 30% had normal albumin excretion vs 10% in TT+TA coding carriers (p=0.01), and rates of CHD (6% vs 14%) and MI (2% vs 14%) were markedly lower. In this extreme glycemic environment, the highest sRAGE producers (TT plus strand) may maintain enough decoy activity to partially offset the AGE burden.

A note on the evidence paradox. The literature on −374T/A contains genuine heterogeneity: the same functional allele appears protective in non-diabetic cardiovascular studies and in poorly controlled T1D, yet harmful in diabetic retinopathy meta-analyses. The likely explanation is that sRAGE and membrane RAGE co-scale with RAGE expression, and their net effect depends critically on the ambient AGE load. The evidence level for this SNP is rated moderate, not strong, because of these context-dependent inconsistencies. Single-genotype actions focus on the best-replicated risk associations (diabetic microvascular complications), where multiple cohorts and a meta-analysis converge.

Practical Actions

The actionable consequence of carrying the T plus-strand allele (−374A coding) depends on metabolic context. For users with normal glucose metabolism, the clinical significance of this SNP alone is modest; the main priority is protecting against future hyperglycemia, which would convert the elevated RAGE expression from a complex mixed signal into a clear-cut driver of microvascular damage. For anyone with prediabetes or diabetes, this variant is a strong reason to pursue tight glycemic control and regular screening for early microvascular complications (retina, kidney).

Dietary advanced glycation end-products — formed by high-heat cooking and abundant in processed foods — add to endogenous AGE production and further activate RAGE-signaling. Reducing dietary AGE intake through cooking method changes (moist heat over dry high-heat) is the most directly mechanism-specific intervention available for RAGE pathway variants.

Interactions

rs1800624 is frequently co-analyzed with rs2070600 (Gly82Ser) as part of an AGER haplotype. Peng et al. (2022)¹²¹² Peng et al. (2022)
Peng Y et al. Genetically modified circulating levels of AGEs and their soluble receptor with risk and mortality of breast cancer. Cancers, 2022 showed that rs2070600 and rs1800624 together dose-dependently predict sRAGE levels, and specific haplotype combinations interact with high AGE exposure to confer breast cancer risk. Users carrying both the rs2070600 T allele (reduced sRAGE shedding) and rs1800624 T allele (elevated total RAGE expression) may experience compounding effects on the AGE-RAGE axis — elevated RAGE surface density with impaired sRAGE buffering simultaneously. This combination warrants a compound action covering both variants (see interaction_candidates below).